Key Growth Opportunities in Global Biotech Investment 2024: Acquiring Rare Disease-focused Biopharma Companies and Investing in Precision Medicine Platform Technology-based Biotech Companies
May 27, 2024 04:29 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Global Biotech Investment, 2024" report has been added to ResearchAndMarkets.com's offering. In this analysis, the report...
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the...
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
May 24, 2024 08:37 ET
|
Stereotaxis, Inc.
Stereotaxis has received CE Mark recertification under the EU’s new Medical Device Regulation (MDR) regulatory framework for all available devices.
Life Science Technical Accounting CPE Update (2-Day Virtual Conference: September 17-18, 2024) - Understand the Latest Accounting Changes in Key Areas
May 24, 2024 07:32 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Life Science Technical Accounting CPE Update 2024" conference has been added to ResearchAndMarkets.com's offering. This conference will cover the...
Single Domain Antibody Platforms MarketResearch 2024-2031: Strategic Collaborations Driving Expansion, Focus on Pioneering Cancer Treatments, US Leads Innovations
May 24, 2024 04:28 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Single Domain Antibody Platforms Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:00 ET
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Cytokinetics Announces Pricing of Public Offering of Common Stock
May 22, 2024 23:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its...
Cytokinetics Announces Proposed Public Offering of Common Stock
May 22, 2024 16:02 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500...
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a...
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
May 22, 2024 12:57 ET
|
SOHM, Inc.
CHINO HILLS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN)– a leading generic pharmaceutical and upstart biotechnology company, is proud to announce its ongoing...